Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients (SAMAS)
Diabetes is a chronic disease characterized by chronic hyperglycaemia, causing microvascular and macrovascular complications. The latter lead to various disabilities: blindness, end-stage renal failure, nerve damage, formation of leg ulcers, and atherosclerosis. In people with type 2 diabetes, the probability of these atherosclerosis associated complications is twice as high as in people without diabetes. Cardiovascular diseases are also the main cause of mortality in people with diabetes.
Preventive measures are therefore crucial. In people with type 2 diabetes, in addition to good glycaemic control, the choice of antidiabetic drugs is also important. Large-scale research has shown that certain glucagon-like peptide (GLP-1) receptor agonists, in addition to improving the regulation of diabetes, also have a significant effect on reducing the macrovascular complications. It is now possible to use semaglutide, a GLP-1 receptor agonist, in the tablet form. Semaglutide lowers blood sugar only when the blood sugar value rises, due to food in the digestive tract, Thus, not increasing the risk of hypoglycaemia. In addition, semaglutide has a significant effect on weight loss and very beneficial, protective effects on the cardiovascular system. Large studies have shown that in its injectable form, it significantly reduces the incidence of cardiovascular death in patients with type 2 diabetes.
Therefore, the aim of the present study is to examine how semaglutide provides protective effects on the cardiovascular system and reduces the risk of diabetes type 2 associated complications.
The present study will include 100 people with type 2 diabetes and last for 12 months. The subjects will receive a semaglutide oral tablet daily in addition to their current treatment (combination of metformin and a sulphonyl urea). At the beginning of the study, after 6 months and at the end of the study (after 12 months of treatment), a detailed clinical examination will be performed and blood will be taken for laboratory parameters. In addition to basic blood tests, inflammatory and oxidative stress parameters, as well as lipid fractions parameters will also be assessed. Ultrasound examination of the changes in the carotid arteries and measures of additional properties of the arteries will also be performed. The confidentiality of the data of the participants in the research will be ensured, as the data obtained during the investigation will be encrypted before processing.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Miodrag Janic, MD, PhD
- Phone Number: +38640303383
- Email: miodrag.janic@kclj.si
Study Contact Backup
- Name: Mojca Lunder, MD, PhD
- Phone Number: +38641527618
- Email: mojca.lunder@kclj.si
Study Locations
-
-
-
Ljubljana, Slovenia
- Recruiting
- UMC Ljubljana, Diabetes Outpatient Clinic
-
Contact:
- Miodrag Janic
- Email: miodrag.janic@kclj.si
-
Contact:
- Mojca Lunder
- Email: mojca.lunder@kclj.si
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- type 2 diabetes
- therapy including at least metformin 1000 mg and sulphonyl urea at least half of the maximal dose
- BMI > or = 30 kg/m2
- HbA1c < or = 8,5%
- associated risk factors including smoking, dyslipidaemia, arterial hypertension, chronic kidney disease stage 1 to 3.
Exclusion Criteria:
- therapy with injectable GLP-1 receptor agonist ongoing or was taking place in the last year
- manifested cardiovascular disease
- heart failure
- chronic kidney disease stages 4 and 5
- advanced liver disease
- proliferative retinopathy or maculopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Interventional Arm
Beside metformin and sulphonyl urea treatment, the active, interventional arm, will be receiving Semaglutide Oral Tablets as per protocol, 3 mg for the first month, 7 mg in the second month and 14 mg form the third month onwards.
|
Semaglutide Oral Tablets will be introduced to the active arm as per protocol for regular therapy introduction.
Other Names:
|
|
NO_INTERVENTION: Comparative Arm
This group will not be receiving the additional therapy besides metformin and sulphonyl urea treatment.
After 6 months a revaluation of glycemic control will be performed, if needed, rescue therapy with basal insulin will be implemented.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in morphological arterial wall characteristics
Time Frame: 1 year
|
Ultrasonographic assessment of cIMT (in millimetres)
|
1 year
|
|
Change in functional arterial wall characteristics
Time Frame: 1 year
|
Endothelial function assessment by EndoPAT
|
1 year
|
|
Change in structural arterial wall characteristics
Time Frame: 1 year
|
Arterial stiffness assessment by Sphygmocor device (in meters per second)
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in atherogenic small dense low-density lipoproteins (sdLDL)
Time Frame: 1 year
|
Assessment by gel electrophoresis
|
1 year
|
|
Change in glycated haemoglobin (HbA1c)
Time Frame: 1 year
|
Assessment by biochemical methods
|
1 year
|
|
Change in high sensitivity C-reactive protein (hsCRP)
Time Frame: 1 year
|
Assessment by biochemical methods
|
1 year
|
|
Correlations between changes in rate of cIMT reduction, % of endothelial function improvement and rate of arterial stiffness reduction on one hand and changes in concentration of sdLDL, % of HbA1c and concentration of hsCRP on the other
Time Frame: 1 year
|
Statistical methods
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Andrej Janež, Prof, University Medical Centre Ljubljana
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UMCLjubljana20210043
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.